

Christian Hampp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2919297/publications.pdf>

Version: 2024-02-01

44
papers

1,190
citations

394421

19
h-index

377865

34
g-index

45
all docs

45
docs citations

45
times ranked

1860
citing authors

#	ARTICLE	IF	CITATIONS
1	Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines. <i>European Journal of Pediatrics</i> , 2022, 181, 841-845.	2.7	0
2	Calibration of Chronic Lung Disease Severity as a Risk Factor for Respiratory Syncytial Virus Hospitalization. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 317-325.	1.3	2
3	Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. <i>Diabetes Care</i> , 2020, 43, 90-97.	8.6	36
4	Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 9-17.	1.9	34
5	Usability of encounter data for Medicaid comprehensive managed care vs traditional Medicaid fee-for-service claims among pregnant women. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 30-38.	1.9	2
6	The Role of Unit-Dose Child-Resistant Packaging in Unintentional Childhood Exposures to Buprenorphine-Naloxone Tablets. <i>Drug Safety</i> , 2020, 43, 189-191.	3.2	5
7	Validation of algorithms to estimate gestational age at birth in the Medicaid Analytic eXtract-Quantifying the misclassification of maternal drug exposure during pregnancy. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1414-1422.	1.9	14
8	Cancer Risk Associated with Lorcaseerin The FDA's Review of the CAMELLIA-TIMI 61 Trial. <i>New England Journal of Medicine</i> , 2020, 383, 1000-1002.	27.0	88
9	Validation of mother-infant linkage using Medicaid Case ID variable within the Medicaid Analytic eXtract (MAX) database. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1222-1230.	1.9	8
10	Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users. <i>Pharmaceutical Medicine</i> , 2019, 33, 29-43.	1.9	4
11	Misclassification in Assessment of First Trimester In-utero Exposure to Drugs Used Proximally to Conception: the Example of Letrozole Utilization for Infertility Treatment. <i>American Journal of Epidemiology</i> , 2019, 188, 418-425.	3.4	10
12	Utilization of drugs with pregnancy exposure registries during pregnancy. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 604-611.	1.9	11
13	Enrollment and Retention in 34 United States Pregnancy Registries Contrasted with the Manufacturer's Capture of Spontaneous Reports for Exposed Pregnancies. <i>Drug Safety</i> , 2018, 41, 87-94.	3.2	18
14	Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 30-37.	1.9	10
15	Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. <i>Diabetes Care</i> , 2018, 41, 39-48.	8.6	21
16	Pioglitazone and bladder cancer: FDA's assessment. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 117-118.	1.9	21
17	A systematic review of pregnancy exposure registries: examination of protocol-specified pregnancy outcomes, target sample size, and comparator selection. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 208-214.	1.9	35
18	Recommendations on the use and nonuse of the p value in biomedical research. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 1262-1266.	1.0	4

#	ARTICLE	IF	CITATIONS
19	Sentinel Modular Program for Propensity Score-Matched Cohort Analyses. <i>Epidemiology</i> , 2017, 28, 838-846.	2.7	32
20	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs. <i>Annals of Internal Medicine</i> , 2016, 164, 705.	3.9	91
21	Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology. <i>Drug Safety</i> , 2016, 39, 261-270.	3.2	10
22	Notes from the Field: Pediatric Emergency Department Visits for Buprenorphine/Naloxone Ingestion - United States, 2008-2015. <i>Morbidity and Mortality Weekly Report</i> , 2016, 65, 1148-1149.	15.1	24
23	Patient understanding of drug risks: an evaluation of medication guide assessments. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 518-525.	1.9	22
24	Editorial Commentary: Can a Reduced-Dose Prophylaxis Schedule Provide Adequate Coverage Against Respiratory Syncytial Virus Infection?. <i>Clinical Infectious Diseases</i> , 2015, 61, 515-516.	5.8	2
25	Emergency Hospitalizations for Unsupervised Prescription Medication Ingestions by Young Children. <i>Pediatrics</i> , 2014, 134, e1009-e1016.	2.1	69
26	Use of Antidiabetic Drugs in the U.S., 2003-2012. <i>Diabetes Care</i> , 2014, 37, 1367-1374.	8.6	179
27	Appropriateness of Age Thresholds for Respiratory Syncytial Virus Immunoprophylaxis in Moderate-Preterm Infants. <i>JAMA Pediatrics</i> , 2013, 167, 1118.	6.2	50
28	Validity of Laboratory-based Surveillance for Detection of Respiratory Syncytial Virus Seasons. <i>American Journal of Epidemiology</i> , 2013, 177, 841-851.	3.4	9
29	Use of Prescription Antiobesity Drugs in the United States. <i>Pharmacotherapy</i> , 2013, 33, 1299-1307.	2.6	89
30	Prevalence, Trends, and Patterns of Use of Antidiabetic Medications Among Pregnant Women, 2001-2007. <i>Obstetrics and Gynecology</i> , 2013, 121, 106-114.	2.4	22
31	Methodological Concerns Regarding Cost-effectiveness Analysis of Palivizumab in Florida Medicaid - Reply. <i>JAMA Pediatrics</i> , 2012, 166, 968.	3.0	1
32	Effectiveness of palivizumab prophylaxis in infants and children in Florida. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 53-60.	1.9	15
33	An algorithm to identify preterm infants in administrative claims data. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 640-650.	1.9	21
34	Feasibility of Short-Term Infusion of Magnesium Sulfate in Pediatric Patients With Status Asthmaticus. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2012, 17, 150-154.	0.5	15
35	Invasive Fungal Infections in Lung Transplant Recipients Not Receiving Routine Systemic Antifungal Prophylaxis: 12-Year Experience at a University Lung Transplant Center. <i>Pharmacotherapy</i> , 2011, 31, 537-545.	2.6	17
36	Review of A Large Clinical Series: Once- Versus Twice-Daily Enoxaparin for Venous Thromboembolism Prophylaxis in High-Risk Trauma Patients. <i>Journal of Intensive Care Medicine</i> , 2011, 26, 111-115.	2.8	20

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications. JAMA Pediatrics, 2011, 165, 498.	3.0	75
38	Longitudinal Study of Optic Cup Progression in Children. Journal of Pediatric Ophthalmology and Strabismus, 2011, 48, 151-156.	0.7	18
39	Palivizumab Utilization and Compliance: Trends in Respiratory Syncytial Virus Prophylaxis in Florida. Journal of Pediatrics, 2010, 156, 953-959.e1.	1.8	27
40	Small Budget Impact Is a Result of Flawed Assumptions and Ignores Questionable Cost-Effectiveness for RSV Prophylaxis. Value in Health, 2010, 13, 684.	0.3	2
41	Longitudinal study of optic cup progression in children. Journal of AAPOS, 2010, 14, e24-e25.	0.3	0
42	Root cause analysis and subsequent intervention to improve first dose antibiotic turnaround time for hospitalized pediatric patients. Journal of Pediatric Pharmacology and Therapeutics, 2010, 15, 182-8.	0.5	3
43	Cost-Utility Analysis of Rimonabant in the Treatment of Obesity. Value in Health, 2008, 11, 389-399.	0.3	53
44	Response to Respiratory Syncytial Virus. Southern Medical Journal, 2008, 101, 212-213.	0.7	1